Physician profile

Robert A Woods

Internal Medicine · Hanford, CA

NPI 1386697514

$432.67

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$155.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Actelion Pharmaceuticals US, INC. $118.08 2023 Uptravi, Opsumit
Merck Sharp & Dohme LLC $100.00 2020
Novo Nordisk INC $92.17 2019-2024 Ozempic, Rybelsus
Amgen INC. $43.90 2019-2020
Amarin Pharma, INC. $21.46 2019
Bioventus LLC $17.37 2021
Glaxosmithkline, LLC. $15.08 2024 Trelegy Ellipta
Sanofi-Aventis U.S. LLC $13.21 2019
Pfizer INC. $11.40 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert A Woods

$432.67

in general payments reported 2019-2025

Years
2019-2024
Top company
Actelion Pharmaceuticals US, INC.

https://glasscript.com/doctor/62286/robert-a-woods

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.